



Monkeypox Vaccination and Therapeutics

Guest Editors:

Dr. Mana Rao

1. Essen Medical Associates, The Bronx, New York, NY 10453, USA
2. ArchCare, New York, NY 10016, USA

Dr. Amesh Adalja

School of Public Health, Johns Hopkins University, Baltimore, MD, USA

Deadline for manuscript
submissions:

closed (15 November 2023)

Message from the Guest Editors

Monkeypox has wreaked global havoc amid the Coronavirus disease of 2019 (COVID-19). While avoiding contact with infectious sources remains paramount for infection prevention, vaccines directed against the *Monkeypox virus* have been added as a tool in our armament of defences against Monkeypox. The aims of vaccination include pre-exposure prophylaxis for at-risk individuals. Novel strategies being applied include post-exposure prophylaxis (PEP) and expanded post-exposure prophylaxis, also known as PEP ++, with the hope to curb disease transmission and decrease morbidity as a result of clinical disease.

The aim of this Special Issue is to feature articles that focus on the 2022 Monkeypox public health emergency, including, but not limited to, vaccination, pre-exposure prophylaxis, post-exposure prophylaxis, expanded post-exposure prophylaxis (PEP ++), and use of antiviral agents. Original articles, reviews, short communications, and commentaries are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com